glp-1/gcgr dual agonist GCGR: A Key Target in Glucose Metabolism-DIMA BIOTECH Media Centre | EASD
Description
This glucose-dependent mechanism reduces hypoglycemia risk compared to insulin or sulfonylureas
Yang, H
Lilly has submitted orforglipron for approval in more than 40 countries, with launches expected in each market following regulatory clearance
doi: 10.1016/j.peptides.2017.11.017
